Spain Blackout Investigation Shows EU Grids Need More Resilience
Preliminary findings of an investigation into a wide-ranging blackout in Spain earlier this year show that European power grids need to improve resilience, according to a report from the European Network of Transmission System Operators for Electricity.
The group, known as ENTSO-E, has assembled a panel of experts to pore over data from Spanish grid operators and power producers to find out what exactly happened in April that suddenly caused millions across the country to lose electricity. Preliminary results show that a cascading series of disconnections of electricity generation and unusual voltage increases were the most likely reason for the blackout, according to an update published Wednesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Biochip Market Global Outlook Report 2025, with Focus on Microarrays and Lab-on-a-Chip
Discover comprehensive insights into the global biochip market, providing revenue analysis, trends, and forecasts to 2029. Examine segmented data by product type, technology, application, and region, and explore sustainability, ESG developments, and key players like Abbott and Agilent Technologies. Global Biochip Market Market Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Biochip Market: Microarrays and Lab-on-a-Chip" report has been added to global market for biochip was valued at $16.1 billion in 2024 and is estimated to reach $27.8 billion by 2029, at a compound annual growth rate (CAGR) of 11.6% from 2024 through global biochip market is witnessing significant growth, driven by the increasing demand for rapid and accurate diagnostic solutions, advances in genomics and proteomics, and the rising adoption of personalized medicine. Biochips, which combine several biochemical assays onto a miniaturized platform, are transforming disciplines like drug discovery, disease diagnosis and biomarker studies. Microarrays and lab-on-a-chip technology allow high-throughput screening, allowing researchers and clinicians to analyze biological samples more quickly and increasing incidence of infectious and chronic diseases and point-of-care testing needs drive biochip use in hospitals, pharmaceutical firms and research centers. Technological advances in nanotechnology, microfluidics and biosensors also improve biochip performance, making them more sensitive, cost-effective and scalable. With government initiatives and increased R&D investments in biotechnology and healthcare, the market is poised for substantial expansion in coming years. Comprehensive market sizing and forecasting will enable stakeholders to identify high-growth segments and regions, understand competitive dynamics and make informed decisions for strategic planning during the forecast period. The report focuses on the significant trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses patents and emerging technologies related to the report concludes with an analysis of the competitive landscape, which provides the ranking and shares of key companies in the global biochip market. There is also a dedicated section on company profiles that provides details about leading companies in the company profiles offer detailed information about business segments, financials, product portfolios and recent developments. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, with estimates for 2024 and a forecast for 2025 through Scope 76 data tables and 56 additional tables An analysis of the current and future global markets for biochip diagnostic products and technologies Analyses of global market trends, with historic revenue data from 2021 to 2024, and projected CAGRs through 2029 Estimates of the size of and revenue prospects for the global biochip market, along with a market share analysis by product type, technology, application, end-user vertical, and region Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macro-economic factors A look at the major commercial biochip products and the future potential of each key market segment, emerging technologies, clinical trials, and other new developments Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading biotech companies Analysis of the industry structure, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Company profiles of major players within the industry, including Abbott, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., and BioMerieux Key Attributes: Report Attribute Details No. of Pages 136 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $16.1 Billion Forecasted Market Value (USD) by 2029 $27.8 Billion Compound Annual Growth Rate 11.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview and Market Definition Technology Background Technological Infrastructure and Data Integration Chapter 3 Market Dynamics Market Drivers Rising Demand for Point-of-Care Diagnostics Increasing Investment and Funding in Biochip and Microarray Research Activities Increasing Prevalence of Cancer Generating Demand for Personalized Treatments Market Restraints and Challenges High Costs Associated with Developing and Implementing Biochip Technology Technical Challenges Market Opportunities Technological Advances and Automation in the Biochip industry Growing Volume of Clinical Research Chapter 4 Regulatory Landscape Market Regulations by Agency The U.S. Federal Regulation CMS Regulation FDA Regulation FTC Regulation Canada European Union The U.K. China Japan Australia International Standards and Guidelines Chapter 5 Emerging Technologies and Developments Artificial Intelligence in Biochip Technology for Biomedicine Advances in DNA and Protein Microarrays 3D Microarrays and Organoid-on-a-Chip Hydrogel-Based Microarrays Other Types of 3D Microarrays Chapter 6 Market Segmentation Analysis Global Biochip Market by Product Microarrays (Array-Based Biochips) Microfluidic Biochips (Lab-on-a-Chip) Biochip Equipment and Software Biochip Consumables and Kits Global Biochip Market by Technology Microarray Technology Microfluidics Technology Global Biochip Market by Application Genomics Proteomics Disease Diagnostics Drug Discovery and Development Global Biochip Market by End User Academic and Research Institutes Biopharmaceutical Companies Hospitals and Diagnostic Centers Geographic Breakdown Global Biochip Market by Region Market Size and Forecast North America Europe Asia-Pacific Rest of World (ROW) Chapter 7 Competitive Intelligence Industry Structure Breakthrough Technologies and Product Launches Top Company Rankings Key Strategies Adopted by Companies Collaborations and Partnerships New Product Launch Expansion and Investment Mergers and Acquisitions Chapter 8 Sustainability in the Biochip Market: An ESG Perspective Introduction to ESG ESG Performance in the Biochip Market ESG Practices in the Biochip Industry Environmental Performance Social Performance Governance Performance ESG Risk Ratings Company Profiles Abbott Agilent Technologies Inc. Biomerieux Bio-Rad Laboratories Inc. F. Hoffmann-La Roche Ltd. Ibiochips Illumina Inc. Li-Cor Biotech Micronit Nutcracker Therapeutics Inc. Qiagen Randox Laboratories Ltd. Revvity Standard Biotools Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Global Biochip Market Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Nvidia and University of Bristol debut UK's fastest AI supercomputer in sovereign AI push
Nvidia (NVDA) and the University of Bristol debuted the UK's Isambard-AI supercomputer on Thursday, part of Nvidia's push into so-called sovereign AI, or AI supercomputers built for individual nations. The fastest supercomputer in the country and one of the most energy-efficient supercomputers globally, the Isambard-AI supercomputer combines 5,448 Nvidia Grace Hopper superchips through a series of liquid-cooled HPE server cabinets packed with 440 GPUs each. The system is meant to perform research on everything from materials science to drug discovery to large language models designed for UK-specific languages such as Welsh. Impressively, according to University of Bristol professor Simon McIntosh-Smith, the entire system came together in less than two years. Normally, it takes more than three years to complete similar projects, McIntosh-Smith, who also heads the Bristol Centre for Supercomputing (BriCS), told Yahoo Finance. Researchers and companies will need to apply for access to the Isambard-AI supercomputer via the UK government's Department for Science, Innovation, and Technology. Supercomputers, however, don't just run individual tasks at once. Depending on the time of day, such systems can run a host of different experiments at the same time, helping to improve overall efficiency While the Isambard-AI supercomputer is powerful as far as research computers go, it's relatively small compared to the massive datacenter-scale systems companies like Amazon (AMZN), Google (GOOG, GOOGL), Meta (META), and Microsoft (MSFT) currently run. Those warehouse-sized computers require gigawatts, or 1 billion watts, of electricity to power tens of thousands of GPUs. The Isambard-AI supercomputer, meanwhile, uses 5 megawatts, or 5 million watts. According to McIntosh-Smith, the team at BriCS chose to use a liquid cooling solution rather than traditional air cooling with fans to keep the Isambard-AI from overheating, because it allowed them to pack more GPUs into a smaller space while improving overall energy efficiency. The university is also working on a pilot program that will use the hot wastewater from the supercomputer to heat campus facilities and eventually nearby homes and businesses. While the University of Bristol officially flipped the switch on Isambard-AI on Thursday, McIntosh-Smith said some researchers have already been running experiments on a test version of the system. Those include work on vaccines for Alzheimer's disease and image recognition to help machines better identify skin cancer. The Isambard-AI supercomputer is just one example of Nvidia's push into sovereign AI, which represents a new revenue stream for the company beyond individual tech companies. In May, CEO Jensen Huang attended an event held in Saudi Arabia where President Trump announced that he would allow Nvidia to sell thousands of GPUs to companies within the country. The administration also set up a plan to sell hundreds of thousands of chips to the United Arab Emirates, but officials are holding off on moving forward with the deal over concerns China could gain access to the technology, the Wall Street Journal reported Wednesday. And in June, Nvidia touted its expansion in Europe, announcing that companies across France, the UK, Germany, and Italy will build out or expand on their AI infrastructure. "Every industrial revolution begins with infrastructure. AI is the essential infrastructure of our time, just as electricity and the internet once were," Huang said in a statement at the time. "With bold leadership from Europe's governments and industries, AI will drive transformative innovation and prosperity for generations to come." The US still accounts for the majority of Nvidia's sales, making up $61.2 billion of the company's $130.4 billion in total revenue in its latest fiscal year. Taiwan and China made up $20.5 billion and $17.1 billion, respectively. Singapore saw $23.6 billion in sales, but Nvidia said the majority of those shipments are simply invoiced in the country and shipped elsewhere. Email Daniel Howley at dhowley@ Follow him on X/Twitter at @DanielHowley. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
an hour ago
- Gizmodo
8 Healthy ‘Three-Parent' Babies Born in UK Using Pioneering IVF Technique
So-called 'three-parent' babies are thriving in the U.K. New clinical trial research shows that several healthy children in the country have been born with the DNA of three people. Doctors at Newcastle University led the study, which involved around two dozen women with a high risk of passing down harmful mutations of their mitochondria to their children. So far, eight kids have been born using an in vitro fertilization (IVF) technique that replaces a mother's damaged mitochondrial DNA with that of a donor, all of whom appear to be disease-free. The findings seem to validate this new approach to preventing these genetic disorders. 'As parents, all we ever wanted was to give our child a healthy start in life. Mitochondrial donation IVF made that possible,' said the mother of a girl born with the method in a statement from the university. 'After years of uncertainty, this treatment gave us hope—and then it gave us our baby. We look at them now, full of life and possibility, and we're overwhelmed with gratitude. Science gave us a chance.' Mitochondria are the cell's primary source of energy, but only a tiny slice of our genetic material is responsible for creating them. This mitochondrial DNA (mtDNA) is found outside the nucleus, unlike the rest of our DNA, and the genes for making mitochondria are only inherited from our mothers. Certain mutations of mtDNA are known to cause serious diseases, and women whose eggs carry these variants can pass them down to their children. The technique pioneered by Newcastle researchers sought to get around this risk in a relatively simple way. They use standard IVF to create a fertilized egg with the mother's and father's DNA, then remove the nucleus. This nucleus is inserted into a donor egg that had its nucleus removed, which is finally transplanted into the mother's uterus for a hopefully successful pregnancy. If all goes well, the resulting child carries all the nuclear DNA of their parents and the healthy mtDNA of the donor. The researchers enrolled 22 women carrying harmful mtDNA variants to undergo the IVF procedure. These women were compared to a group of women who instead received preimplantation genetic testing (PGT), a common screening technique that can select for healthy mitochondria prior to IVF (for some women, a harmful mtDNA variant will only show up occasionally in their eggs). Eight women who underwent mitochondrial donation had live births, while another woman has an ongoing pregnancy. None of the children—four boys, four girls, and a set of identical twins—have shown signs of mitochondrial disease so far, and all are reaching their developmental goals on schedule. The success rate of the technique (36%) was also similar to PGT (41%). The results were published across two studies in the New England Journal of Medicine. The findings do point to some current limitations of mitochondrial donation. Some of the children had mitochondria carrying harmful mutations, for instance. Even in these children, however, most of their cells still carried healthy mitochondria, and their levels of mutated mitochondria are likely low enough to prevent disease from emerging. But this result will merit further monitoring of the children, and it suggests the IVF method can be improved to lessen the chance of it happening. Earlier versions of mitochondrial donation have been developed, though these were eventually banned in countries like the U.S. for being too dangerous. The UK has slowly but steadily been laying the groundwork for this newer and safer technique to be cleared for widespread use (the country officially allowed the first treatment in 2018, now seven years ago). So while there may be important questions left to answer, many women living with this genetic risk may soon have a new option available that will allow them to have children of their own.
